Aptamer Group (LSE:APTA), the York-based developer of synthetic binding molecules for life sciences, has confirmed it will publish full-year results for the 12 months to 30 June 2026 on Tuesday, 13 October 2026. The notice, issued on 7 October, sets up a results briefing and an online investor presentation hosted by chief executive Dr Arron Tolley and chief financial officer Andrew Rapson. The results will add detail to a July trading update that pointed to Revenue growth and the group's first licensing income.

What the Company Does

Aptamer develops Optimer binders, engineered nucleic acid molecules designed as an alternative to antibodies. The company provides fee-for-service discovery and development work for pharmaceutical, diagnostics and biotechnology customers, and is increasingly seeking to license its technology so that it earns recurring, higher-margin income. Its programmes span diagnostics, research tools and therapeutics, including a targeted radiopharmaceutical project launched in March 2026.

Latest Developments

In its trading update of 13 July 2026, Aptamer said it expected revenue of about £1.5m for the 2026 financial year, around 25% higher than the £1.2m reported a year earlier. Growth came from fee-for-service work and initial licensing receipts under agreements signed in December 2025 with Twist Bioscience and Alphazyme. The sales pipeline stood at £4.8m at 30 June, up 55% from £3.1m at the January half-year update, and the company had a £0.6m order book carried into the 2027 financial year. Contracts mentioned included roughly £769,000 with a top five pharmaceutical partner and about £190,000 with a top 10 global pharmaceutical company.

Other recent announcements included the start of an Ebola diagnostic test programme in July, a rapid testing programme for fortified foods in June, and a programme and technical development update in late June. The company also appointed a joint corporate broker in August. Management described licensing as a potential meaningful, high-margin revenue stream over time.

Financial Picture

Aptamer strengthened its Balance Sheet in the spring. In March 2026 it raised £4.275m gross through a placing and subscription at 0.6p per share, with participants receiving one Warrant for every three shares, exercisable at 0.9p within two years. A retail offer of up to £0.5m ran alongside. The July update cited net proceeds of £4.1m and said the cash runway extends into at least 2028. The proceeds are earmarked mainly for an artificial intelligence model for RNA-binding proteins and in vivo data for the radiopharmaceutical programme, with the remainder supporting Working Capital and a path towards EBITDA breakeven. No Dividend is paid.

Sector and index Context

Aptamer is one of the smaller life sciences companies in the FTSE AIM All Share Index. Early-stage biotechnology and tools businesses on AIM have generally relied on periodic share funding while they build commercial revenues, and investor sentiment towards the sector has often hinged on Partnership announcements and licensing deals.

Key Risks

Revenue remains modest relative to the company's cost base, and the shift towards licensing depends on partners successfully commercialising products. The large number of new shares and warrants issued in the March fundraise has diluted existing holders. Pipeline conversion is uncertain, and contract timing can cause year-to-year swings.

What to Watch Next

The 13 October results should confirm audited revenue, losses and the year-end cash position. Investors will look for an update on licensing income, conversion of the £4.8m pipeline into contracts, progress with the radiopharmaceutical and Ebola programmes, and any timetable for reaching EBITDA breakeven.